The SAM bioinformatics market is expected to grow from US$ 859.12 million in 2022 to US$ 1,982.28 million by 2028; it is estimated to grow at a CAGR of 15.0% from 2022 to 2028.
Personalized medicine is an emerging practice of medicine in which the genetic profile of an individual is used to lead decisions regarding prevention, diagnosis, and treatment of disease. The genetic profile of a patient assists doctors in precisely calculating a patient's susceptibility to specific diseases and allows them to prescribe the patient a proper medication with reduced side effects. In personalized medicine, bioinformatics can be used to explore any possible mutations or gene variants affecting a patient's response to a particular drug/treatment by analyzing the patient's genome sequencing or microarray gene expression. The patient-specific medication is developed through bioinformatics tools. Bioinformatics devices may furnish better conclusions at the genomic level with prior identification of infection and better focus on treatment through improved personalized medicine. Therefore, the rising demand for personalized medicine, especially for rare diseases and cancer, is expected to provide growth opportunities for the bioinformatics market.
Personalized medicine is an emerging practice of medicine in which the genetic profile of an individual is used to lead decisions regarding prevention, diagnosis, and treatment of disease. The genetic profile of a patient assists doctors in precisely calculating a patient's susceptibility to specific diseases and allows them to prescribe the patient a proper medication with reduced side effects. In personalized medicine, bioinformatics can be used to explore any possible mutations or gene variants affecting a patient's response to a particular drug/treatment by analyzing the patient's genome sequencing or microarray gene expression. The patient-specific medication is developed through bioinformatics tools. Bioinformatics devices may furnish better conclusions at the genomic level with prior identification of infection and better focus on treatment through improved personalized medicine. Therefore, the rising demand for personalized medicine, especially for rare diseases and cancer, is expected to provide growth opportunities for the bioinformatics market.
Market Overview
The bioinformatics market in SAM is broadly segmented into Brazil, Argentina, and Rest of SAM. Brazil dominated the market in 2022. Brazil is gaining traction in the adoption of genomic research. Initially, Brazil invested US$ 11 million to begin a genomics program through various projects. Currently, it is receiving funding from numerous organizations worldwide. This initiative fostered a strong genomics influence on the healthcare sector in the country. Also, the developments in genomics, artificial intelligence, and remote sensing have enormous potential to enhance human, animal, and environmental health and enable this progress. In Brazil, the biotechnology market has experienced several activities in terms of industrial-scale activities and healthcare. Brazil is known for its research and investment in industrial biotechnology, predominantly regarding cellulosic sugars and agribusiness. The Brazilian stakeholders, policymakers, and public investors have promoted the advancement of industrial biotechnology in Brazil. The trade groups in Brazil aim to enhance the current patent laws to support biotechnology advancements, R&D, laboratory infrastructures, and knowledge transfer by increasing training capabilities.SAM Bioinformatics Market Segmentation
The SAM bioinformatics market is segmented based on product, application, sector, and country.- Based on product, the SAM bioinformatics market is segmented into knowledge management tools, bioinformatics platforms, and bio informative services. The bioinformatics platforms segment held the largest market share in 2022.
- Based on application, the SAM bioinformatics market is segmented into genomics, chemo informatics and drug design, proteomics, transcriptomics, metabolomics, and others. The genomics segment held the largest market share in 2022.
- Based on sector, the SAM bioinformatics market is segmented into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, forensic biotechnology, and others. The medical biotechnology segment held the largest market share in 2022.
- Based on country, the SAM bioinformatics market has been categorized into Brazil, Argentina, and Rest of SAM. Further, Brazil dominated the market in 2022. Agilent Technologies, Inc.; Bruker Corporation; Dassault Systèmes; Eurofins Scientific; Illumina, Inc.; PerkinElmer Inc.; QIAGEN; and Thermo Fisher Scientific Inc. are the leading companies operating in the SAM bioinformatics market.
Table of Contents
1. Introduction
3. Research Methodology
4. SAM Bioinformatics Market - Market Landscape
5. SAM Bioinformatics Market - Key Market Dynamics
6. Bioinformatics Market - SAM Analysis
7. SAM Bioinformatics Market Analysis - By Product
8. SAM Bioinformatics Market Analysis - By Application
9. SAM Bioinformatics Market Analysis - By Sector
10. SAM Bioinformatics Market - Country Analysis
11. Industry Landscape
12. COMPANY PROFILES
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Agilent Technologies, Inc.
- Bruker Corporation
- Dassault Systèmes
- Eurofins Scientific
- Illumina, Inc.
- Perkinelmer Inc.
- Qiagen
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | November 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( $ | $ 859.12 Million |
| Forecasted Market Value ( $ | $ 1982.28 Million |
| Compound Annual Growth Rate | 15.0% |
| No. of Companies Mentioned | 8 |
